SOUTH SAN FRANCISCO, Calif.—(BUSINESS WIRE)—Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce an agreement with Pfizer Inc. (NYSE: PFE) to license the Distributed Bio SuperHuman Platform for the identification of novel antibodies for use as therapeutic agents.
Under the terms of the agreement, Distributed Bio will transfer and license its proprietary SuperHuman 2.0 antibody discovery platform to Pfizer, which will utilize the SuperHuman Antibody Library to perform screening activities against Pfizer-selected targets. Pfizer has also secured access to continued improvements to the SuperHuman Platform. Distributed Bio will receive an undisclosed annual licensing fee and future payments upon achievement of specified preclinical and clinical milestones.
“The SuperHuman Platform represents the culmination of a decade of our research in computational library design,” says Jacob Glanville, Co-Founder and Chief Science Officer of Distributed Bio. “From analyzing thousands of human immune systems with our machine learning AbGenesis platform, we have harvested from nature the rules of making exceptional therapeutic repertoires. The result is a library of 76 billion antibodies that contains over 5,000 hits against any antigen, including hundreds of picomolar binders, all thermostable, non-immunogenic, pre-screened by human blood and therapeutically developed in advance to avoid engineering delays downstream.
“We believe our platform is superior in generating a greater number of molecules than can be generated by other technologies, and we hope this will help enable our collaborators at Pfizer to more quickly search for ultra-high affinity, species-cross reactive and highly specific therapeutic antibodies.”
Contacts
Distributed Bio Inc.
Giles Day
CEO
Tel: +1 415 489 0246
Email: giles@distributedbio.com
